Salubris(SZ:002294) Zheng Quan Zhi Xing·2025-08-19 16:22Core Viewpoint - The Shenzhen Xinlitai Pharmaceutical Co., Ltd. has successfully passed the review of its 2025 semi-annual report and the special report on the use of raised funds, confirming compliance with legal and regulatory requirements [1][2]. Group 1 - The sixth supervisory board of the company held its tenth meeting on August 7, 2025, where all three attending supervisors unanimously approved the 2025 semi-annual report and its summary [1]. - The supervisory board confirmed that the procedures for preparing and reviewing the semi-annual report complied with relevant laws, regulations, and the company's articles of association, ensuring the report accurately reflects the company's actual situation without any false records or misleading statements [1]. - The company’s special report on the storage and use of raised funds for the first half of 2025 was also unanimously approved, indicating no violations in the use of these funds [1][2]. Group 2 - During the reporting period, the company adhered strictly to the regulations of the Shenzhen Stock Exchange and its own fundraising management measures, ensuring that there were no changes in the use of raised funds that could harm shareholder interests [2]. - The actual investment projects align with the promised investment projects, complying with relevant laws and regulations [2]. - The special report on the storage and use of raised funds accurately reflects the company's situation regarding these funds [2].